Ponatinib is a third-generation TKI approved in CML patients with refractory CML or Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) and those harboring the BCR-ABL1T315I mutant. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.